{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T05:38:25Z","timestamp":1761197905410,"version":"build-2065373602"},"reference-count":57,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Accurate staging of prostate cancer (PCa) at initial diagnosis and at biochemical recurrence is important to determine prognosis and the optimal treatment strategy. To date, treatment of metastatic PCa has mostly been based on the results of conventional imaging with abdominopelvic computed tomography (CT) and bone scintigraphy. However, these investigations have limited sensitivity and specificity which impairs their ability to accurately identify and quantify the true extent of active disease. Modern imaging modalities, such as those based on the detection of radioactively labeled tracers with combined positron emission tomography\/computed tomography (PET\/CT) scanning have been developed specifically for the detection of PCa. Novel radiotracers include 18F-sodium fluoride (NaF), 11C-\/18F-fluorocholine (FCH), 18F-fluordihydrotestosterone (FDHT), 68Gallium and 18F-radiolabeled prostate-specific membrane antigen (e.g., 68Ga-PSMA-11, 18F-DCFPyL). PET\/CT with these tracers outperforms conventional imaging. As a result of this, although their impact on outcome needs to be better defined in appropriate clinical trials, techniques like prostate-specific membrane antigen (PSMA) PET\/CT have been rapidly adopted into clinical practice for (re)staging PCa. This review focuses on nuclear imaging for PCa bone metastases, summarizing the literature on conventional imaging (focusing on CT and bone scintigraphy\u2014magnetic resonance imaging is not addressed in this review), highlighting the prognostic importance of high and low volume metastatic disease which serves as a driver for the development of better imaging techniques, and finally discussing modern nuclear imaging with novel radiotracers.<\/jats:p>","DOI":"10.3390\/diagnostics11010117","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T11:52:32Z","timestamp":1610538752000},"page":"117","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Nuclear Imaging for Bone Metastases in Prostate Cancer: The Emergence of Modern Techniques Using Novel Radiotracers"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4590-6589","authenticated-orcid":false,"given":"Wietske I.","family":"Luining","sequence":"first","affiliation":[{"name":"Department of Urology, Prostate Cancer Network Netherlands, Amsterdam University Medical Center, VU University, 1081 HV Amsterdam, The Netherlands"},{"name":"Department of Radiology &amp; Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Center, VU University, 1081 HV Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8298-575X","authenticated-orcid":false,"given":"Dennie","family":"Meijer","sequence":"additional","affiliation":[{"name":"Department of Urology, Prostate Cancer Network Netherlands, Amsterdam University Medical Center, VU University, 1081 HV Amsterdam, The Netherlands"},{"name":"Department of Radiology &amp; Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Center, VU University, 1081 HV Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max R.","family":"Dahele","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cancer Center Amsterdam, Amsterdam University Medical Center, VU University Amsterdam, 1081 HV Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3419-3368","authenticated-orcid":false,"given":"Andr\u00e9 N.","family":"Vis","sequence":"additional","affiliation":[{"name":"Department of Urology, Prostate Cancer Network Netherlands, Amsterdam University Medical Center, VU University, 1081 HV Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9447-2305","authenticated-orcid":false,"given":"Daniela E.","family":"Oprea-Lager","sequence":"additional","affiliation":[{"name":"Department of Radiology &amp; Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Center, VU University, 1081 HV Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018","volume":"103","author":"Ferlay","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Mottet, N., van den Bergh, R.C.N., Briers, E., Van den Broeck, T., Cumberbatch, M.G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., and Gillessen, S. (2020). EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur. Urol.","DOI":"10.1016\/j.eururo.2020.09.042"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System","volume":"40","author":"Epstein","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"Whittington","year":"1998","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00345-018-2182-1","article-title":"(68)Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: A systematic review","volume":"36","author":"Corfield","year":"2018","journal-title":"World J. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","article-title":"Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis","volume":"77","author":"Perera","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s00256-019-03230-z","article-title":"Comparison of PSMA-PET\/CT, choline-PET\/CT, NaF-PET\/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: A systematic review and meta-analysis","volume":"48","author":"Zhou","year":"2019","journal-title":"Skeletal. Radiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12149-019-01343-y","article-title":"(18)F-NaF-PET\/CT for the detection of bone metastasis in prostate cancer: A meta-analysis of diagnostic accuracy studies","volume":"33","author":"Sheikhbahaei","year":"2019","journal-title":"Ann. Nucl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00256-014-1903-9","article-title":"Comparison of choline-PET\/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: A meta-analysis","volume":"43","author":"Shen","year":"2014","journal-title":"Skeletal. Radiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.eururo.2009.12.023","article-title":"When to perform bone scan in patients with newly diagnosed prostate cancer: External validation of the currently available guidelines and proposal of a novel risk stratification tool","volume":"57","author":"Briganti","year":"2010","journal-title":"Eur. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1097\/01.ju.0000123981.03084.06","article-title":"Baseline staging of newly diagnosed prostate cancer: A summary of the literature","volume":"171","author":"Abuzallouf","year":"2004","journal-title":"J. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.21037\/tau.2020.03.20","article-title":"Comparison of cross-sectional imaging techniques for the detection of prostate cancer lymph node metastasis: A critical review","volume":"9","author":"Lebastchi","year":"2020","journal-title":"Transl. Androl. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1148\/radiol.2541090361","article-title":"Lymphatic Metastases from Pelvic Tumors: Anatomic Classification, Characterization, and Staging","volume":"254","author":"McMahon","year":"2010","journal-title":"Radiology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.urology.2016.02.014","article-title":"Current Status of Lymph Node Imaging in Bladder and Prostate Cancer","volume":"96","author":"Kiss","year":"2016","journal-title":"Urology"},{"key":"ref_18","first-page":"366","article-title":"Tumor Localization of 16\u03b2-18F-Fluoro-5\u03b1-Dihydrotestosterone Versus 18F-FDG in Patients with Progressive, Metastatic Prostate Cancer","volume":"45","author":"Larson","year":"2004","journal-title":"J. Nucl. Med."},{"key":"ref_19","first-page":"101","article-title":"Imaging in the diagnosis and management of prostate cancer","volume":"6","author":"Taneja","year":"2004","journal-title":"Rev. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0090-4295(00)00994-8","article-title":"Prostate-specific antigen best practice policy\u2014Part II: Prostate cancer staging and post-treatment follow-up","volume":"57","author":"Carroll","year":"2001","journal-title":"Urology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0090-4295(96)00161-6","article-title":"Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy","volume":"48","author":"Flanigan","year":"1996","journal-title":"Urology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","article-title":"The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: A meta-analysis","volume":"63","author":"Heesakkers","year":"2008","journal-title":"Clin. Radiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00345-015-1669-2","article-title":"Is there still a role for computed tomography and bone scintigraphy in prostate cancer staging? An analysis from the EUREKA-1 database","volume":"34","author":"Gabriele","year":"2016","journal-title":"World J. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.eururo.2011.08.026","article-title":"Contemporary role of androgen deprivation therapy for prostate cancer","volume":"61","author":"Pagliarulo","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: Long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"55S","DOI":"10.2967\/jnumed.115.169730","article-title":"Evaluation of Prostate Cancer Bone Metastases with 18F-NaF and 18F-Fluorocholine PET\/CT","volume":"57","author":"Beheshti","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2967\/jnumed.119.229062","article-title":"No Added Value of (18)F-Sodium Fluoride PET\/CT for the Detection of Bone Metastases in Patients with Newly Diagnosed Prostate Cancer with Normal Bone Scintigraphy","volume":"60","author":"Zacho","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13550-019-0531-8","article-title":"Sensitivity of (18)F-fluorodihydrotestosterone PET-CT to count statistics and reconstruction protocol in metastatic castration-resistant prostate cancer","volume":"9","author":"Cysouw","year":"2019","journal-title":"EJNMMI Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2967\/jnumed.118.220111","article-title":"Assessment of Simplified Methods for Quantification of (18)F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer","volume":"60","author":"Kramer","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2013.50.1684","article-title":"Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer","volume":"31","author":"Rathkopf","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","article-title":"Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1\u20132 study","volume":"375","author":"Scher","year":"2010","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s00259-005-1764-5","article-title":"Positron tomographic assessment of androgen receptors in prostatic carcinoma","volume":"32","author":"Dehdashti","year":"2005","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11307-014-0803-7","article-title":"[18F]fluoromethylcholine as a chemotherapy response read-out in prostate cancer cells","volume":"17","author":"Bijnsdorp","year":"2015","journal-title":"Mol. Imaging Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/RLU.0b013e3182867f3c","article-title":"Choline PET or PET\/CT and biochemical relapse of prostate cancer: A systematic review and meta-analysis","volume":"38","author":"Evangelista","year":"2013","journal-title":"Clin. Nucl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","article-title":"Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer","volume":"41","author":"Zechmann","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00259-016-3490-6","article-title":"Comparison of (68)Ga-labelled PSMA-11 and (11)C-choline in the detection of prostate cancer metastases by PET\/CT","volume":"44","author":"Schwenck","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.humpath.2006.11.012","article-title":"Prostate-specific membrane antigen expression as a predictor of prostate cancer progression","volume":"38","author":"Perner","year":"2007","journal-title":"Hum. Pathol."},{"key":"ref_43","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00259-017-3631-6","article-title":"(68)Ga-PSMA-11 PET\/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour","volume":"44","author":"Uprimny","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/pcan.2016.13","article-title":"PET imaging of prostate-specific membrane antigen in prostate cancer: Current state of the art and future challenges","volume":"19","author":"Rowe","year":"2016","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Bodar, Y.J.L., Jansen, B.H.E., van der Voorn, J.P., Zwezerijnen, G.J.C., Meijer, D., Nieuwenhuijzen, J.A., Boellaard, R., Hendrikse, N.H., Hoekstra, O.S., and van Moorselaar, R.J.A. (2020). Detection of prostate cancer with 18F-DCFPyL PET\/CT compared to final histopathology of radical prostatectomy specimens: Is PSMA-targeted biopsy feasible? The DeTeCT trial. World J. Urol.","DOI":"10.1007\/s00345-020-03490-8"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bju.14506","article-title":"Gallium-68-prostate-specific membrane antigen ((68) Ga-PSMA) positron emission tomography (PET)\/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancer","volume":"124","author":"Donswijk","year":"2019","journal-title":"BJU Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s41824-018-0044-0","article-title":"18F-DCFPyL PET\/CT in primary staging of prostate cancer","volume":"2","author":"Wondergem","year":"2018","journal-title":"Eur. J. Hybrid Imaging"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","article-title":"Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer","volume":"17","author":"Szabo","year":"2015","journal-title":"Mol. Imaging Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","article-title":"F-18 labelled PSMA-1007: Biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients","volume":"44","author":"Giesel","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11307-015-0866-0","article-title":"Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer","volume":"17","author":"Dietlein","year":"2015","journal-title":"Mol. Imaging Biol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Wondergem, M., van der Zant, F.M., Broos, W.A.M., Roeleveld, T.A., Donker, R., Ten Oever, D., Geenen, R.W.F., and Knol, R.J.J. (2020). (18)F-DCFPyL PET\/CT for primary staging in 160 high-risk prostate cancer patients; metastasis detection rate, influence on clinical management and preliminary results of treatment efficacy. Eur. J. Nucl. Med. Mol. Imaging.","DOI":"10.1007\/s00259-020-04782-2"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Jansen, B.H.E., Bodar, Y.J.L., Zwezerijnen, G.J.C., Meijer, D., van der Voorn, J.P., Nieuwenhuijzen, J.A., Wondergem, M., Roeleveld, T.A., Boellaard, R., and Hoekstra, O.S. (2020). Pelvic lymph-node staging with (18)F-DCFPyL PET\/CT prior to extended pelvic lymph-node dissection in primary prostate cancer\u2014The SALT trial. Eur. J. Nucl. Med. Mol. Imaging.","DOI":"10.1007\/s00259-020-04974-w"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastases revisited","volume":"8","author":"Weichselbaum","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.eururo.2014.09.004","article-title":"Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: A systematic review of the literature","volume":"67","author":"Ost","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial","volume":"38","author":"Palma","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2020.38.6_suppl.10","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial","volume":"38","author":"Ost","year":"2020","journal-title":"J. Clin. Oncol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/11\/1\/117\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:10:24Z","timestamp":1760159424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/11\/1\/117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["diagnostics11010117"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics11010117","relation":{},"ISSN":["2075-4418"],"issn-type":[{"type":"electronic","value":"2075-4418"}],"subject":[],"published":{"date-parts":[[2021,1,13]]}}}